Elliptic Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Elliptic Laboratories has a total shareholder equity of NOK317.5M and total debt of NOK4.0M, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are NOK356.5M and NOK39.0M respectively.
Key information
1.3%
Debt to equity ratio
NOK 4.00m
Debt
| Interest coverage ratio | n/a |
| Cash | NOK 96.90m |
| Equity | NOK 317.52m |
| Total liabilities | NOK 38.96m |
| Total assets | NOK 356.48m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ELABSO's short term assets (NOK189.3M) exceed its short term liabilities (NOK25.7M).
Long Term Liabilities: ELABSO's short term assets (NOK189.3M) exceed its long term liabilities (NOK13.2M).
Debt to Equity History and Analysis
Debt Level: ELABSO has more cash than its total debt.
Reducing Debt: ELABSO's debt to equity ratio has reduced from 73.6% to 1.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ELABSO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ELABSO has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 22.4% each year.